SEC adopts EDGAR Next - As outlined in this October 22 Cooley alert, the Securities and Exchange Commission (SEC) adopted final ...
The Physicians Committee—and 27 other organizations—are calling on Congress to reject funding for harmful primate experiments ...
A European regulatory committee now recommends approval of the Alzheimer’s treatment lecanemab a few months after rejecting ...
The European Union's drugs regulator on Thursday recommended approval of Eisai and Biogen's Leqembi for some patients with ...
Biogen’s stock rose 1% Thursday, after Europe’s pharmaceutical regulator issued a positive opinion on the Alzheimer’s disease ...
November is Alzheimer's Awareness Month and 7 News met Grand Island couple Tom and Michele Drabik, who shared their experience with the disease.
Researchers at Tel Aviv University have made a fundamental discovery: the NMDA receptor (NMDAR)—long studied primarily for ...
Europe's medicines watchdog on Thursday partially approved a marketing request for a long-awaited new treatment for Alzheimer ...
The U.S. Treasury Department said on Thursday that New York-based insurer MetLife's unit, American Life Insurance Company, ...
The AD risk factors/hits include high exposure to traffic-related air pollution (TRAP) and infections, as well as factors ...
Reversing an earlier decision, European regulators recommended that an Alzheimer’s therapy from Eisai and Biogen should be ...
A key European regulatory panel has reversed course and is now recommending approval of Leqembi, the Alzheimer's drug from Biogen and Eisai. The companies on Thursday said the European Medicines ...